Sunclouds. CytoDyn is also initiating a second
Post# of 148187
Quote:
CytoDyn is also initiating a second COVID-19 trial this week. This trial is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients, double-blinded with a 2:1 ratio (drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks, with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients.
I had not read any press releases after 4:00 P.M. and after your latest post I did read the one at 5:50 P.M(I thought you where referring to te previous one). You are absolutely right, the mistake is still there. It was me not doing the required D.D. thanks for pointing that out and my apologies.
It needs to be changed to 390 and, after the clarification on the video, somebody need so "get their act together" and change the number.